简介：AspatientsinEastAsiaage,theprevalenceofage-relatedandchronicdisease,includingnonvalvularatrialfibrillation,mayincrease.Althoughwarfarinhasbeentheprimarychoiceofanticoagulantforthepreventionofstrokeandsystemicembolicevents,theuseofdirectoralanticoagulants(DOACs)isincreasing.DOACsdonotrequiremonitoringoftheinternationalnormalizedratiotodeterminetheoptimaldose,andhavealowerpotentialforfoodanddruginteractions,improvedbenefit-riskprofiles,andaquickeronsetandoffsetofactionrelativetowarfarin.Thepivotalphase3trialsforeachoftheDOACs–dabigatran,rivaroxaban,apixaban,andedoxaban–includedatleastsomeEastAsianpatients.Additionally,severalclinicaltrialswereconductedspecificallyforEastAsianpatients.ThisreviewdiscussespatternsandpredictorsofanticoagulantuseinEastAsianpatientswithnonvalvularatrialfibrillation,summarizescurrentguidelinerecommendationsforEastAsianpatients,detailstheprimaryresultsdemonstratingthesafetyandefficacyofDOACsinEastAsianpatientsrelativetonon–EastAsianpatients,providesreal-worlddatasupportingthephase3testingresults,andaddressestheclinicalprofileofDOACsinEastAsianpopulations,includingpatientsathighriskofstroke.